^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Renal Cell Carcinoma

Related cancers:
14h
Overexpression of CYP11A1 recovers cell cycle distribution in renal cell carcinoma Caki-1. (PubMed, Cancer Cell Int)
Our findings may suggest promising new therapeutic targets to suppress kidney cancer proliferation without affecting normal cells, eventually improving the survival of patients with cancer.
Journal
|
VIM (Vimentin) • CDC25C (Cell Division Cycle 25C) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
|
VIM expression
1d
A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma. (PubMed, Nat Commun)
An in silico cell-to-cell interaction analysis highlights the CXCL9/CXCL10-CXCR3 axis and the CD70-CD27 axis as potential therapeutic targets. Our findings provide biological insights into the interplay between tumor cells and the ccRCC microenvironment.
Journal
|
CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD70 • CD27 • CXCR3 (C-X-C Motif Chemokine Receptor 3)
1d
Panels of mRNAs and miRNAs for decoding molecular mechanisms of Renal Cell Carcinoma (RCC) subtypes utilizing Artificial Intelligence approaches. (PubMed, Sci Rep)
This study found new panels of mRNAs and miRNAs to distinguish among RCC subtypes, which were able to provide new insights into the underlying responsible mechanisms for the initiation and progression of KIRC and KIRP. The proposed mRNA and miRNA panels have a high potential to be as biomarkers of RCC subtypes and should be examined in future clinical studies.
Journal
|
MIR125A (MicroRNA 125a)
2d
Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis. (PubMed, Biomark Res)
Low expression of miR-637 increases the resistance of colorectal cancer (CRC) and human cholangiocarcinoma (CHOL) cancer cells to three anticancer chemotherapeutics (gemcitabine (dFdC), cisplatin (DDP), and oxaliplatin (OXA)). At the same time, the relationship between the expression levels of miR-637 and its related molecules and the prognosis and pathological characteristics of patients was further summarized. Finally, our work points out the insufficiency of miR-637 in current studies and is expected to provide potential clues for future miR-637-related studies.
Review • Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2)
|
cisplatin • gemcitabine • oxaliplatin
2d
Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade. (PubMed, Front Oncol)
Its dynamic changes during treatment may be used to assess response before radiographic changes are apparent, and these changes may help us delineate mechanisms that underpin both response and resistance to ICI. It also hypothesizes a potential role for γ/δ T cells as effector cells in some cases.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CCR4 (C-C Motif Chemokine Receptor 4) • CD4 (CD4 Molecule) • CCR7 (Chemokine (C-C motif) receptor 7) • KLRB1 (Killer Cell Lectin Like Receptor B1)
|
CXCR4 expression • TNFA-H
2d
PLK4 Is a Potential Biomarker for Abnormal Tumor Proliferation, Immune Infiltration, and Prognosis in ccRCC. (PubMed, Comput Math Methods Med)
Our data suggest that the PLK4 expression is closely related to the level of immune infiltration and the cytokines that exert immune suppression, and IPS was significantly higher in the PLK4 low expression group. The PLK4 expression is associated with the prognosis of ccRCC patients and affects the immune microenvironment of ccRCC, and PLK4 is expected to be a new target for the diagnosis and treatment of ccRCC.
Journal
|
PLK4 (Polo Like Kinase 4) • MIR214 (MicroRNA 214)
|
PLK4 expression
2d
Calbindin S100A16 Promotes Renal Cell Carcinoma Progression and Angiogenesis via the VEGF/VEGFR2 Signaling Pathway. (PubMed, Contrast Media Mol Imaging)
Intervention of s100a16 can promote the progression and angiogenesis of renal cell carcinoma through the VEGF/VEGFR2 signal transduction pathway and lead to poor prognosis of renal cell carcinoma. These findings suggest a potential target for the development of anticancer strategies for renal cancer.
Journal
|
CALB1 (Calbindin 1) • S100A16 (S100 Calcium Binding Protein A16)
|
KDR expression • VEGFA expression
2d
BACH1 promotes clear cell renal cell carcinoma progression via upregulating oxidative stress-related tumorigenicity. (PubMed, Cancer Sci)
BACH1 involvement in other OSR-linked pathways, including inflammatory responses, angiogenesis, and mammalian target of rapamycin signaling, was further revealed by RNA sequencing analysis of BACH1-knockdown cells. In conclusion, the crucial role of BACH1 in the pathogenesis and poor prognosis of ccRCC through the promotion of OSRs is suggested.
Journal
|
BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • HMOX1 (Heme Oxygenase 1) • BACH1 (BTB Domain And CNC Homolog 1)
|
HMOX1 expression
2d
Cerebrospinal Fluid Interleukin-6 in Immune Checkpoint Inhibitor-Induced Autoimmune Meningoencephalitis. (PubMed, Tohoku J Exp Med)
A 70-year-old woman (Case 2) who received an initial administration of nivolumab plus ipilimumab for renal cell carcinoma developed alterations of consciousness. No abstract available
Journal • Checkpoint inhibition
|
IL6 (Interleukin 6)
|
IL6 elevation • IL6-H
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
2d
Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms' tumor. (PubMed, Pediatr Surg Int)
Hence, extensive profiling of OGs and TGs association of major-signaling pathways in Wilms' tumor cases may aid in disease diagnosis. PBRM1 (up-regulated in 91.67% of cases), ERBB2 and EGFR (down-regulated in 91.66 and 91.66% of cases, respectively) could be marker genes. However, validation of all relevant results in a larger number of samples is required.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • FGFR3 (Fibroblast growth factor receptor 3) • HRAS (Harvey rat sarcoma viral oncogene homolog) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • PBRM1 (Polybromo 1) • KMT2D (Lysine Methyltransferase 2D) • KMT2C (Lysine Methyltransferase 2C) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • CDH1 (Cadherin 1) • WT1 (WT1 Transcription Factor) • SMARCB1 • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • EP300 (E1A binding protein p300) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2) • GATA2 (GATA Binding Protein 2) • GATA1 (GATA Binding Protein 1) • PRDM1 (PR/SET Domain 1)
2d
Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation. (PubMed, Cell Death Dis)
Our results indicate separate novel mechanisms for sunitinib and sorafenib resistance, which both lead to MCPIP1 inhibition and ccRCC progression. The presented study suggests caution in the treatment of RCC with TKIs, which may lead to the unintended outcome of tumor progression.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • IL6 (Interleukin 6) • CDH1 (Cadherin 1) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • MMP9 (Matrix metallopeptidase 9) • CDH5 (Cadherin 5) • IRAK1 (Interleukin 1 Receptor Associated Kinase 1)
|
CDH1 expression
|
sorafenib • Sutent (sunitinib)
2d
The Multifaceted Role of Signal Peptide-CUB-EGF Domain-Containing Protein (SCUBE) in Cancer. (PubMed, Int J Mol Sci)
This review presents key features of SCUBE family members, and their structure and functions, and highlights their contribution in the development and progression of cancer. A comprehensive understanding of the role of SCUBE family members offers novel strategies for cancer therapy.
Review • Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • TGFB1 (Transforming Growth Factor Beta 1) • EGF (Epidermal growth factor) • SMAD2 (SMAD Family Member 2)
2d
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. (PubMed, Int J Mol Sci)
Considering the rising number of oncological patients treated with ICIs and the severity of their potential adverse effects, a good understanding and continuous investigation of cardiac irAEs is of the utmost importance. This systematic review aimed to revise recent publications (between 2016-2022) on ICI-induced cardiac toxicities and highlight the therapeutical approach and evolution in the selected cases.
Review • Journal • Adverse events • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
3d
Papillary Renal Neoplasm With Reverse Polarity. (PubMed, Arch Pathol Lab Med)
In our study, all cases exhibited an indolent clinical course. This supports that PRNRP has characteristic morphologic and molecular features.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • L1CAM (L1 cell adhesion molecule) • GATA3 (GATA binding protein 3)
|
KRAS mutation
3d
Cancer risks by sex and variant type in PTEN Hamartoma Tumor Syndrome. (PubMed, J Natl Cancer Inst)
Females have a different breast cancer risk depending on their PTEN germline variant. PHTS patients are predominantly at risk of breast (females), endometrial and thyroid cancer. This should be the main focus of surveillance. These lower, more unbiased and personalized risks provide guidance for optimized cancer risk management.
Journal
|
PTEN (Phosphatase and tensin homolog)
3d
Development and validation of a novel necroptosis-related score to improve the outcomes of clear cell renal cell carcinoma. (PubMed, Front Genet)
Notably, the prognosis of ccRCC could be effectively guided by combining the N-Scores and external clinical indicators. In conclusion, N-Scores could be served as a robust and effective biomarker to improve the prognosis outcomes and targeted therapy of ccRCC.
Journal • Tumor Mutational Burden
|
TMB (Tumor Mutational Burden)
3d
Identification of ST3GAL5 as a prognostic biomarker correlating with CD8 T cell exhaustion in clear cell renal cell carcinoma. (PubMed, Front Immunol)
In our own ccRCC cohort (n = 45), immunohistochemistry and immunofluorescence staining confirmed that ST3GAL5 overexpression was accompanied by high CD8 T cell infiltration with the increased exhaustion markers. Altogether, ST3GAL5 as a promising prognostic biomarker with CD8 T cell exhaustion in ccRCC is indicated.
Journal
|
CD8 (cluster of differentiation 8)
|
CD8 expression • CD8-H
3d
Contribution of functional imaging in the follow-up of a patient with pituitary macroadenoma, paraganglioma, renal tumor, and SDHC gene variant. (ENEA 2022)
Treatment with cabergoline, 1.5 mg per week, normalized prolactin in 3 months and stabilized the tumor...This mutation was responsible for jugulo-tympanic paraganglioma, macroprolactinoma, and an RCC. New functional imaging techniques recently developed in vivo (MRI spectroscopy and 68Ga-DOTATOC PET) and in vitro (SDHB immunohistochemistry) allow optimal management of patients with SDHx mutation.
Clinical
|
SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • SDHC (Succinate Dehydrogenase Complex Subunit C)
|
SDHC mutation
|
cabergoline
3d
The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. (PubMed, Cancer Treat Res Commun)
Less is known about rhabdoid dedifferentiation from either a clinical, biological, or therapeutic perspective. In this focused review, we will discuss the prognostic implications, outcomes with systemic therapy, and underlying biology in RCC with either sarcomatoid or rhabdoid dedifferentiation present.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
3d
Retrospective data • Journal
|
CRP (C-reactive protein)
3d
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1b, N=60, Active, not recruiting, NeoTX Therapeutics Ltd. | Recruiting --> Active, not recruiting
Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TPBG (Trophoblast Glycoprotein)
|
HER-2 negative • TPBG positive
|
Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
3d
The Lonidamine Derivative H2-Gamendazole Reduces Cyst Formation in Polycystic Kidney Disease. (PubMed, Am J Physiol Renal Physiol)
Thus, H2-GMZ treatment decreases Cl secretion, cell proliferation, cell motility, and cyst growth. These properties, along with its reported low toxicity, suggest that H2-GMZ might be an attractive candidate for treatment of ADPKD.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4) • EGF (Epidermal growth factor) • CFTR (CF Transmembrane Conductance Regulator) • PKD1 (Polycystin 1) • PRKD1 (Protein Kinase D1)
3d
Effects of Genistein on Common Kidney Diseases. (PubMed, Nutrients)
Third, genistein has beneficial effects on a variety of kidney diseases (including acute kidney disease, kidney cancer, and different chronic kidney diseases), such as reducing symptoms, delaying disease progression, and improving prognosis. Therefore, this paper reviews animal and human studies on the protective effects of genistein on the kidney in vivo and in vitro to provide a reference for clinical research in the future.
Review • Journal
|
ER (Estrogen receptor)
3d
Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator. (PubMed, J Immunother Cancer)
Altogether, these data revealed VSSP as a novel regulator of myeloid biology that mitigates MDSCs in cancer patients and reinstates a more normal myeloid phenotype that potentially favors immune activation over immune suppression.
Journal
|
IRF8 (Interferon Regulatory Factor 8)
3d
A signature based on chromatin regulation and tumor microenvironment infiltration in clear cell renal cell carcinoma. (PubMed, Epigenomics)
The high-risk subtype was characterized by increased tumor mutation burden, whereas a low-risk score was characterized by an increase in chromatin regulator expression and better overall survival. This research has constructed a signature based on chromatin regulation in localized ccRCC.
Journal • Tumor Mutational Burden
|
TMB (Tumor Mutational Burden)
4d
The convergence of tumor suppressors on interferon pathway in kidney cancer and its therapeutic implication. (PubMed, Am J Physiol Cell Physiol)
The tumors with secondary mutations that dampen the negative feedback loop might be exquisitely sensitive to its reactivation, and pharmacological activation of ISGF3 could be an effective method to treat ccRCC patients either alone or in combination with other effective therapies. In this review, we examine the relevance of the type I IFN pathway to ccRCC, synthesize our current knowledge of the ccRCC tumor suppressors in its regulation, and explore how this may impact the future treatment of ccRCC patients.
Review • Journal
|
PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • VHL (von Hippel-Lindau tumor suppressor) • KDM5C (Lysine Demethylase 5C) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)
|
PBRM1 mutation • BAP1 mutation • SETD2 mutation
4d
Calcium oxalate crystals trigger epithelial-mesenchymal transition and carcinogenic features in renal cells: a crossroad between kidney stone disease and renal cancer. (PubMed, Exp Hematol Oncol)
Finally, COM enhanced invading capability, cell-aggregate formation, chemoresistance to cisplatin, and secretion of an angiogenic factor (VEGF). These data indicate that COM crystals trigger epithelial-mesenchymal transition (EMT) and several carcinogenic features in the non-cancerous renal cells. These mechanisms may explain and strengthen the association between KSD and RCC.
Journal
|
PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • CDH1 (Cadherin 1) • FN1 (Fibronectin 1) • VIM (Vimentin) • TJP1 (Tight Junction Protein 1) • TPX2 (TPX2 Microtubule Nucleation Factor)
|
cisplatin
4d
Identification of an amino acid metabolism-associated gene signature predicting the prognosis and immune therapy response of clear cell renal cell carcinoma. (PubMed, Front Oncol)
Patients with lower risk scores had better overall survival but worse responses to nivolumab. Amino acid metabolic status is closely correlated with tumor microenvironment, response to checkpoint blockade therapy, and prognosis in patients with ccRCC. The established amino acid metabolism-associated gene signature can predict both survival and anti-PD-1 therapy response in patients with ccRCC.
Journal • Gene Signature • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
Opdivo (nivolumab)
4d
Analysis of the prognostic, diagnostic and immunological role of HSP90α in malignant tumors. (PubMed, Front Oncol)
However, we found that the expression level of HSP90AA1 gene in most tumors was not completely consistent with the serum level, and even down-regulated in some tumors. Plasma levels can be used as biomarkers of poor prognosis in some tumors, but it cannot be used as a biomarker for poor prognosis of all tumors, and more in-depth studies are needed.
Journal • BRCA Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-L2 (Programmed Cell Death 1 Ligand 2) • BRCA (Breast cancer early onset) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
4d
Sarcomatoid-associated gene risk index for clear cell renal cell carcinoma. (PubMed, Front Genet)
The molecular characteristics among the SAGRI subgroups were analyzed by multiple methods, and results suggested that the SAGRI-HIGH subgroup may benefit more from immunotherapy to improve prognosis. SAGRI satisfactorily predicted the prognosis of patients with clear cell renal cell carcinoma with or without sarcomatoid differentiation.
Journal
|
NPR3 (Natriuretic Peptide Receptor 3)
4d
Circulating vascular endothelial growth factor and cancer risk: A bidirectional mendelian randomization. (PubMed, Front Genet)
Circulating VEGF has a causal relationship with specific types of cancer. Our findings highlight and confirm the importance of circulating VEGF in the prevention and treatment of colorectal cancer.
Journal
|
VEGFA (Vascular endothelial growth factor A)
4d
Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials. (PubMed, Cancer Treat Res Commun)
Tyrosine kinase inhibitor (TKI) monotherapy is considered the standard of care, and combination strategies with TKIs and immune checkpoint inhibitors are emerging. Genetic profiling and large-scale clinical trials are needed to inform targeted treatment of PRCC.
Journal • IO biomarker
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET mutation
|
Opdivo (nivolumab) • Sutent (sunitinib)
4d
High CENPA expression in papillary renal cell carcinoma tissues is associated with poor prognosis. (PubMed, BMC Urol)
CENPA expression increases within PRCC samples, which predicts dismal PRCC survival. CENPA may become a molecular prognostic marker and therapeutic target for PRCC patients.
Journal
|
PRCC (Proline Rich Mitotic Checkpoint Control Factor) • CENPA (Centromere protein A)
4d
Inhibition of USP1 enhances anticancer drugs-induced cancer cell death through downregulation of survivin and miR-216a-5p-mediated upregulation of DR5. (PubMed, Cell Death Dis)
Pharmacological inhibitors (ML23 and pimozide) and siRNA targeting USP1 induced downregulation of survivin expression...Furthermore, USP1 and survivin protein expression showed a positive correlation, whereas miR-216a-5p and DR5 were inversely correlated in RCC tumor tissues. Taken together, our results suggest two target substrates of USP1 and demonstrate the involvement of survivin and DR5 in USP1-targeted chemotherapy.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5) • FANCD2 (FA Complementation Group D2) • MIR216A (MicroRNA 216a) • PCNA (Proliferating cell nuclear antigen) • TNFRSF10B (TNF Receptor Superfamily Member 10b) • USP1 (Ubiquitin Specific Peptidase 1)
|
BIRC5 expression • BIRC5 overexpression
|
pimozide
4d
Exosomal AP000439.2 from clear cell renal cell carcinoma induces M2 macrophage polarization to promote tumor progression through activation of STAT3. (PubMed, Cell Commun Signal)
Exosomes from ccRCC deliver AP000439.2 to promote M2 macrophage polarization via STAT3, thus enhancing ccRCC progression, indicating exosomal AP000439.2 might be a novel therapeutic target in ccRCC. Video Abstract.
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • TGFB1 (Transforming Growth Factor Beta 1) • IL10 (Interleukin 10) • RELA (RELA Proto-Oncogene)
4d
A novel tumor mutation burden related lncRNA signature identified prognosis and tumor immune microenvironment features in clear cell renal cell carcinoma. (PubMed, Comb Chem High Throughput Screen)
This study successfully developed and validated a novel TMB-related lncRNA signature for individualized prognosis assessment of ccRCC patients.
Journal • Tumor Mutational Burden
|
TMB (Tumor Mutational Burden) • LINC00460 (Long Intergenic Non-Protein Coding RNA 460)
4d
A convolutional neural network model for survival prediction based on prognosis-related cascaded Wx feature selection. (PubMed, Lab Invest)
These findings confirmed that CNN-Cox model is effective in extracting not only prognosis factors but also biologically meaningful gene features. The codes are available at the GitHub website: https://github.com/wangwangCCChen/CNN-Cox .
Journal
|
CDK1 (Cyclin-dependent kinase 1) • NCAPG (Non-SMC Condensin I Complex Subunit G) • ANLN (Anillin Actin Binding Protein) • KIF20A (Kinesin Family Member 20A) • KIF4A (Kinesin Family Member 4A) • RACGAP1 (Rac GTPase activating protein 1)
4d
Phosphoproteomic analysis of FLCN inactivation highlights differential kinase pathways and regulatory TFEB phosphoserines. (PubMed, Mol Cell Proteomics)
The clinically available MAPK inhibitor Ulixertinib showed enhanced toxicity in FLCN cells...Also, we identified that FLCN inactivation resulted in dephosphorylation of TFEB Ser109, Ser114, and Ser122, which may be linked to increased oxidative stress levels in FLCN cells. Together, our study highlights differential phosphorylation of specific kinases and substrates in FLCN renal cells. This provides insight into BHD-associated renal tumorigenesis and may point to several novel candidates for targeted therapies.
Journal
|
EGFR (Epidermal growth factor receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • MAPK1 (Mitogen-activated protein kinase 1) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • FLCN (Folliculin) • EPHB1 (EPH Receptor B1) • TFEB (Transcription Factor EB 2)
|
FLCN mutation
|
ulixertinib (BVD-523) • SER-109
4d
DDX41 expression is associated with tumor necrosis in clear cell renal cell carcinoma and in cooperation with VHL loss leads to worse prognosis. (PubMed, Urol Oncol)
DDX41 expression is associated with TN in ccRCC and leads to a worse prognosis in cooperation with VHL loss.
Journal
|
VHL (von Hippel-Lindau tumor suppressor)
4d
Capsaicin inhibits the migration, invasion and EMT of renal cancer cells by inducing AMPK/mTOR-mediated autophagy. (PubMed, Chem Biol Interact)
Our further results demonstrated that CAP-induced autophagy was mediated by the AMPK/mTOR pathway. In conclusion, our study provides new knowledge of the potential relationship between autophagy and metastasis inhibition induced by CAP, which might be a promising therapeutic strategy in RCC.
Journal
|
AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)
4d
Isoform-resolved mRNA profiling of ribosome load defines interplay of HIF and mTOR dysregulation in kidney cancer. (PubMed, Nat Struct Mol Biol)
In contrast, HIF-dependent alterations in TSS usage are associated with robust changes in translational efficiency in a subset of genes. Analyses of the interplay of HIF and mTOR reveal that specific classes of HIF1A and HIF2A transcriptional target gene manifest different sensitivity to mTOR, in a manner that supports combined use of HIF2A and mTOR inhibitors in treatment of kidney cancer.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • EPAS1 (Endothelial PAS domain protein 1)
4d
Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. (PubMed, Oncotarget)
The efficacy of poly ADP-ribose polymerase inhibitors (PARPis) and temozolomide (TMZ), alone and in combination, was evaluated both in vitro and in vivo. In vivo, treatment with standard dosing of the PARP inhibitor BGB-290 and low-dose TMZ significantly inhibits tumor growth without a significant increase in toxicity. These findings provide the basis for a novel therapeutic strategy exploiting HR deficiency in FH and SDH-deficient RCC with combined PARP inhibition and low-dose alkylating chemotherapy.
Journal • PARP Biomarker
|
SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • FH (Fumarate Hydratase) • KDM4A (Lysine Demethylase 4A)
|
temozolomide • Partruvix (pamiparib)